Cannabinoid formulation for management of depression, anxiety and ptsd, and cannabinoid formulation as a sleep aid

Abstract

Formulations and methods for managing depression, anxiety and/or PTSD are described, for use by individuals in need thereof. The formulations comprise a plurality of cannabinoids and one or more excipient, diluent or carrier. The cannabinoids are present in the formulation in optimized amounts to address these conditions in an amount of: tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) as primary cannabinoids in a weight ratio of from 0-1:4-20:10-25, respectively, such as 1:5:20, 0:20:10 or 0:10:20. Formulations and methods for aiding sleep are also described, for use by individuals in need thereof, such as individuals with insomnia. The formulation comprises a plurality of cannabinoids and one or more excipient, diluent or carrier. The formulation comprises tetrahydrocannabinol (THC), cannabichromene (CBC), and cannabidiol (CBD) as primary cannabinoids in a weight ratio of from 1:0-5:15-25, respectively, such as 1:3:20, 1:0:20 or 1:4:20.

Dependencies are inferred from the claim text.